Membrane Technology & Research Secures $27 Million Investment to Accelerate Global Deployment of Membrane-Based Solutions

NEWARK, Calif.--(BUSINESS WIRE)--Apr 9, 2026--

Membrane Technology & Research, Inc. (MTR), a global leader in membrane-based separation technologies, today announced it has secured a $27 million equity investment led by Climate Investment, with participation from Hartree Partners. Combined with MTR’s commercially-proven and scalable technology platform, this investment strengthens the company’s position to accelerate global deployment in industrial separations and carbon capture applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260409935327/en/

MTR has appointed John Gatlin as Chief Executive Officer, bringing more than 25 years of leadership experience across the energy sector to guide the company’s next phase of growth and commercialization. Mr. Gatlin most recently served as Chief Operating Officer of Flowco Holdings and previously as President of Estis Compression. He holds a B.S. in Petroleum Engineering from University of Texas at Austin and an MBA in Finance from the Wharton School of the University of Pennsylvania.

In addition, Brett Andrews has been appointed Chief Commercial Officer, where he will lead global sales, marketing, and customer engagement to support MTR’s continued growth and worldwide commercial execution.

John Gatlin, Chief Executive Officer of Membrane Technology & Research, Inc., said: “I’m delighted to join MTR at such an exciting time. With the backing of Climate Investment and Hartree Partners, we are well positioned to accelerate commercial deployment of our proven membrane technology platform. In addition to our highly innovative approach to carbon capture, we see significant opportunity in expanding high-value applications such as BTX aromatics recovery and membrane-based acid gas enrichment for Claus plants.”

Brett Andrews, Chief Commercial Officer of Membrane Technology & Research, Inc., added: “With this investment, we are expanding our commercial reach and supporting customers with scalable, cost-effective solutions across a range of industrial applications. We are seeing strong demand for technologies that can be deployed today, and our membrane systems are well positioned to meet that need at scale.”

Patrick Yip, Managing Director and Head of Growth Equity at Climate Investment, stated: “MTR is a leader in membrane-based separations, with highly compelling applications across a range of industrial and energy markets. We are pleased to support, alongside Hartree Partners, the next phase of MTR’s growth as its solutions are increasingly deployed to help industries achieve meaningful emissions reductions and meet decarbonization goals.”

About Membrane Technology & Research, Inc. (MTR)

Membrane Technology & Research, Inc. (MTR) is a global leader in membrane-based gas and vapor separation technologies, with more than 40 years of innovation and over 450 commercial systems deployed worldwide. MTR develops, manufactures, and supplies advanced membrane solutions that enable efficient, cost-effective separations across a wide range of industrial and energy applications.

MTR operates through two core business divisions: MTR Industrial Separations and MTR Carbon Capture.

MTR Carbon Capture is a leading provider of membrane-based carbon capture systems for power generation and industrial applications. MTR’s Polaris® membrane platform offers a modular, scalable, and cost-effective solution that has been validated through more than 15 years of development in collaboration with the U.S. Department of Energy. This work recently culminated in the design and operation of the world’s largest membrane-based carbon capture system at the Dry Fork Station coal power plant in Wyoming, USA.

MTR Industrial Separations delivers a suite of innovative membrane solutions to the petrochemical, natural gas, and refining industries. Focused on improving process efficiency and reducing energy consumption and emissions, MTR partners with leading global companies to provide high-performance separation technologies across critical industrial applications.

For more information, visit www.mtrinc.com and www.mtrccs.com

About Climate Investment

Climate Investment (CI) is an independently managed specialist investor focused on driving industrial decarbonization. The firm provides venture and growth equity capital to innovative companies and partners with industry to accelerate market adoption, create value for infrastructure owners, and deliver measurable greenhouse gas (GHG) impact.

Since its founding in 2017, CI has invested in more than 40 climate technology companies across energy, transportation, buildings, and industrial sectors. Collectively, these investments have contributed to approximately 133 million tonnes of CO₂e emissions reductions between 2019 and 2024.

Climate Investment was founded by member companies of the Oil & Gas Climate Initiative (OGCI), which have invested in CI funds and deployed many of its portfolio innovations to support early commercial development.

For more information, visit www.climateinvestment.com

About Hartree Partners

Hartree Partners is a leading global merchant commodities firm specializing in energy and associated industries. Established more than 25 years ago, the firm is jointly owned by its senior management and funds managed by Oaktree Capital Management.

Hartree has a long-standing track record in proprietary trading and investing across global energy markets. The firm leverages deep expertise in commodity market dynamics and risk management to develop and execute successful trading and investment strategies.

Today, Hartree employs more than 700 people, with approximately 1,000 additional associates across its operating companies, and maintains a strong balance sheet to support trading and principal investment activities.

For more information, visit www.hartreepartners.com

Membrane Technology & Research’s (MTR) carbon capture facility featuring its Polaris™ membrane technology.

GLASGOW, Scotland--(BUSINESS WIRE)--Apr 9, 2026--

Lee Cronin, CEO and founder of Chemify, the deep-tech pioneer of Chemputation – a technological breakthrough that integrates AI- and ML-driven molecular discovery and automated, robotic synthesis – has published three peer-reviewed research papers in close succession, constituting a technological tour de force that validates Chemputation as a new paradigm for how small molecule-drugs and materials are discovered, designed and manufactured.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260409370277/en/

The three publications in PNAS, Nature Communications Chemistry and Nature Communications Biology describe how the Chemputation AI platform can understand and execute instructions to make new molecules from scientific literature, produce them iteratively and how this could be applied to cancer research. Together, these three papers demonstrate the potential of Chemputation to digitize chemistry and become the foundation for the autonomous discovery, manufacturing and generation of high-value molecules at scale.

“Chemputation has been established as a new paradigm, critical for the future of chemical discovery and manufacture, and I’m proud that Chemify is building on these discoveries delivering real molecules using Chemputation AI to our partners,” said Lee Cronin, CEO and founder of Chemify. “Chemputation shifts chemistry from an artisanal practice to an executable, verifiable and shareable technology and opens the door to a future where drugs, materials and entirely new and makeable molecules can be designed, compiled and manufactured as easily as software.”

The three papers were all published within the last two weeks by Lee Cronin and multidisciplinary co-authors from the University of Glasgow, where Cronin has a lab.

Chemify was founded in 2022 as a spin-out from the University of Glasgow, and closed a $50 million Series B financing co-led by Wing Venture Capital and Insight Partners in October of 2025. Chemify opened its first Chemifarm in June of 2025 to revolutionize molecular design and manufacturing, and has a variety of active small molecule research collaborations with multiple biotech, pharmaceutical and institutional partners.

About Chemputation

Chemify’s Chemputation technology merges AI/ML-based design with a universal programming language for chemistry and advanced software and robotics, empowering partners to move seamlessly from novel concept to makeable compound. The closed-loop workflow accelerates iteration and enhances design confidence to achieve high-quality hits and leads with exceptional speed and precision.

About Chemify

Chemify is reimagining the discovery and synthesis of novel molecules for medicines and advanced materials by turning digital code into physical compounds through Chemputation —its fusion of robotics and AI. Headquartered in Glasgow, Scotland, the company was founded by Lee Cronin to digitalize chemistry at global scale for the benefit of humanity. Learn more at Chemify.io and follow @ChemifyX on X/Twitter.

Lee Cronin, CEO and founder of Chemify, the deep-tech pioneer of Chemputation – a technological breakthrough that integrates AI- and ML-driven molecular discovery and automated, robotic synthesis – has published three peer-reviewed research papers in close succession, constituting a technological tour de force that validates Chemputation as a new paradigm for how small molecule-drugs and materials are discovered, designed and manufactured. The three publications in PNAS, Nature Communications Chemistry and Nature Communications Biology describe how the Chemputation AI platform can understand and execute instructions to make new molecules from scientific literature, produce them iteratively and how this could be applied to cancer research.